Stock listing
Euronext:OSE OSE Immunotherapeutics SA Action
Home listing (Euronext) of OSE Immunotherapeutics SA
Follow OSE Immunotherapeutics SA into a list and get an email when it puts out news.
Share price · EURONEXT:OSE
€1.95 EUR -0.15 (-7.3%)
Close on Oct 30, 2026
- Day range
- €1.95 – €2.18 EUROct 30, 2026
- Volume
- 305,968 sharesOct 30, 2026
- Market cap
- €48.26M EURAt the close on Oct 30, 2026 · price × 24.72M shares outstanding
- 52-week range
- €1.95 – €6.10 EURLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
- Traded on an average day
- €403,837 EURMedian day 124,255 shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:OSE · Home | €1.952 EUR | -0.154 (-7.3%) | 305,968 | €2.17 | €2.18 | €1.952 | €2.106 | Close on Oct 30, 2026 |
| LSE:0RAD | €2.122 EUR | +0.106 (+5.3%) | 6,189 | €2.05 | €2.128 | €2.05 | €2.016 | Close on Oct 27, 2026 |
| Frankfurt:6OP | €2.106 EUR | +0.113 (+5.7%) | — | €2.106 | €2.106 | €2.106 | €1.993 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · EURONEXT:OSE · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €1.952 | -0.154 | -7.3% | €2.17 | €2.18 | €1.952 | 305,968 | |
| €2.106 | -0.084 | -3.8% | €2.20 | €2.20 | €2.106 | 167,230 | |
| €2.19 | +0.066 | +3.1% | €2.14 | €2.33 | €2.122 | 534,530 | |
| €2.124 | +0.066 | +3.2% | €2.05 | €2.144 | €2.038 | 145,682 | |
| €2.058 | +0.054 | +2.7% | €2.02 | €2.098 | €2.02 | 115,812 | |
| €2.004 | -0.038 | -1.9% | €2.068 | €2.068 | €1.976 | 106,689 | |
| €2.042 | -0.028 | -1.4% | €2.068 | €2.084 | €2.004 | 119,657 | |
| €2.07 | -0.03 | -1.4% | €2.10 | €2.106 | €2.05 | 74,989 | |
| €2.10 | +0.02 | +1.0% | €2.08 | €2.126 | €2.00 | 231,674 | |
| €2.08 | -0.08 | -3.7% | €2.24 | €2.24 | €2.052 | 268,874 | |
| €2.16 | -0.098 | -4.3% | €2.26 | €2.26 | €2.16 | 172,095 | |
| €2.258 | +0.198 | +9.6% | €2.058 | €2.262 | €2.04 | 262,197 | |
| €2.06 | +0.016 | +0.8% | €2.052 | €2.098 | €2.01 | 79,845 | |
| €2.044 | -0.084 | -3.9% | €2.14 | €2.148 | €2.04 | 134,675 | |
| €2.128 | -0.006 | -0.3% | €2.134 | €2.156 | €2.098 | 73,935 | |
| €2.134 | +0.022 | +1.0% | €2.12 | €2.186 | €2.12 | 64,784 | |
| €2.112 | -0.024 | -1.1% | €2.16 | €2.19 | €2.062 | 93,120 | |
| €2.136 | -0.024 | -1.1% | €2.16 | €2.16 | €2.108 | 43,606 | |
| €2.16 | +0.072 | +3.4% | €2.108 | €2.204 | €2.108 | 176,457 | |
| €2.088 | -0.026 | -1.2% | €2.114 | €2.212 | €2.082 | 249,850 | |
| €2.114 | -0.06 | -2.8% | €2.15 | €2.218 | €2.09 | 124,706 | |
| €2.174 | -0.066 | -2.9% | €2.23 | €2.236 | €2.162 | 71,945 | |
| €2.24 | -0.012 | -0.5% | €2.242 | €2.27 | €2.17 | 117,031 | |
| €2.252 | -0.116 | -4.9% | €2.364 | €2.38 | €2.25 | 144,968 | |
| €2.368 | +0.126 | +5.6% | €2.22 | €2.44 | €2.19 | 413,805 | |
| €2.242 | -0.218 | -8.9% | €2.43 | €2.45 | €2.24 | 320,479 | |
| €2.46 | -0.138 | -5.3% | €2.642 | €2.642 | €2.456 | 104,668 | |
| €2.598 | +0.016 | +0.6% | €2.728 | €2.788 | €2.578 | 360,766 | |
| €2.582 | -0.008 | -0.3% | €2.59 | €2.604 | €2.548 | 47,367 | |
| €2.59 | -0.04 | -1.5% | €2.63 | €2.63 | €2.536 | 87,018 | |
| €2.63 | -0.016 | -0.6% | €2.66 | €2.748 | €2.61 | 94,848 | |
| €2.646 | +0.032 | +1.2% | €2.55 | €2.65 | €2.538 | 67,806 | |
| €2.614 | -0.052 | -2.0% | €2.66 | €2.726 | €2.536 | 107,462 | |
| €2.666 | -0.048 | -1.8% | €2.686 | €2.74 | €2.642 | 120,511 | |
| €2.714 | +0.006 | +0.2% | €2.70 | €2.722 | €2.61 | 70,162 | |
| €2.708 | -0.04 | -1.5% | €2.738 | €2.836 | €2.702 | 128,208 | |
| €2.748 | -0.138 | -4.8% | €2.886 | €2.958 | €2.748 | 159,220 | |
| €2.886 | -0.112 | -3.7% | €3.01 | €3.01 | €2.844 | 151,290 | |
| €2.998 | -0.06 | -2.0% | €3.09 | €3.09 | €2.922 | 87,060 | |
| €3.058 | +0.072 | +2.4% | €3.038 | €3.096 | €2.97 | 94,245 | |
| €2.986 | -0.084 | -2.7% | €3.10 | €3.10 | €2.922 | 244,384 | |
| €3.07 | -0.142 | -4.4% | €3.24 | €3.258 | €3.062 | 196,258 | |
| €3.212 | +0.016 | +0.5% | €3.198 | €3.32 | €3.17 | 117,228 | |
| €3.196 | -0.02 | -0.6% | €3.20 | €3.242 | €3.172 | 69,800 | |
| €3.216 | +0.026 | +0.8% | €3.208 | €3.238 | €3.18 | 57,350 | |
| €3.19 | -0.034 | -1.1% | €3.23 | €3.31 | €3.19 | 107,049 | |
| €3.224 | +0.008 | +0.2% | €3.238 | €3.248 | €3.17 | 80,728 | |
| €3.216 | +0.004 | +0.1% | €3.202 | €3.24 | €3.186 | 57,101 | |
| €3.212 | +0.024 | +0.8% | €3.21 | €3.242 | €3.162 | 72,226 | |
| €3.188 | -0.146 | -4.4% | €3.328 | €3.346 | €3.18 | 112,844 | |
| €3.334 | -0.01 | -0.3% | €3.324 | €3.34 | €3.27 | 115,625 | |
| €3.344 | -0.03 | -0.9% | €3.38 | €3.44 | €3.306 | 127,004 | |
| €3.374 | +0.064 | +1.9% | €3.34 | €3.484 | €3.274 | 258,021 | |
| €3.31 | -0.04 | -1.2% | €3.35 | €3.356 | €3.29 | 66,482 | |
| €3.35 | +0.032 | +1.0% | €3.344 | €3.39 | €3.28 | 135,458 | |
| €3.318 | -0.044 | -1.3% | €3.342 | €3.412 | €3.26 | 210,834 | |
| €3.362 | +0.01 | +0.3% | €3.398 | €3.544 | €3.322 | 401,374 | |
| €3.352 | +0.048 | +1.5% | €3.27 | €3.43 | €3.186 | 195,633 | |
| €3.304 | +0.074 | +2.3% | €3.262 | €3.34 | €3.226 | 128,782 | |
| €3.23 | -0.10 | -3.0% | €3.35 | €3.396 | €3.23 | 124,255 | |
| €3.33 | +0.114 | +3.5% | €3.226 | €3.33 | €3.226 | 165,644 | |
| €3.216 | -0.046 | -1.4% | €3.24 | €3.332 | €3.216 | 133,483 | |
| €3.262 | +0.05 | +1.6% | €3.222 | €3.294 | €3.202 | 123,876 | |
| €3.212 | +0.052 | +1.6% | €3.20 | €3.312 | €3.184 | 127,239 | |
| €3.16 | -0.046 | -1.4% | €3.216 | €3.282 | €3.156 | 105,831 | |
| €3.206 | -0.002 | -0.1% | €3.23 | €3.33 | €3.172 | 206,993 | |
| €3.208 | -0.01 | -0.3% | €3.21 | €3.316 | €3.19 | 132,650 |
- Ticker
- Euronext:OSE
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Euronext
- Currency
- EUR
What changed lately
Latest news release · Oct 29, 2026
OSE Immunotherapeutics Reports Additional Positive Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer
Latest deck · Sep 30, 2026
Investor Presentation (September 2026)
Investor deck · 32 slides
Latest news
OSE Immunotherapeutics Reports Additional Positive Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer
Oct 29, 2026
Closed €1.95 (-7.3%) on Oct 30, 2026
OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare Conference
Oct 15, 2026
Closed €2.26 (+9.6%) on Oct 15, 2026
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Oct 7, 2026
Closed €2.14 (-1.1%) on Oct 7, 2026
OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update
Sep 28, 2026
Closed €2.37 (+5.6%) on Sep 28, 2026
OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting
Sep 23, 2026
Closed €2.60 (+0.6%) on Sep 23, 2026
OSE Immunotherapeutics annonce la présentation des principaux résultats de l'étude de Phase 2 Combi-TED de Tedopi® dans le cancer du poumon non à petites cellules au Congrès 2026 de l’ESMO
Sep 22, 2026
Closed €2.60 (+0.6%) on Sep 23, 2026
OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients
Sep 9, 2026
Closed €2.75 (-4.8%) on Sep 10, 2026
OSE Immunotherapeutics se félicite de l’inclusion du premier patient traité par Veloxis dans l’étude de phase 2 RENGEVITY-201 évaluant le pegrizeprument (VEL-101) dans la prévention du rejet d’organe chez les patients transplantés rénaux
Sep 8, 2026
Closed €2.89 (-3.7%) on Sep 9, 2026
OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026
Aug 27, 2026
Closed €3.19 (-1.1%) on Aug 28, 2026
Decks
Investor Presentation (September 2026)
Investor deck · 32 slides · Sep 30, 2026
Investor Presentation (July 2026)
Investor deck · 31 slides · Jul 20, 2026
Investor Presentation (June 2026)
Investor deck · 31 slides · Jun 22, 2026
Investor Presentation (April 2026)
Investor deck · 31 slides · Apr 20, 2026
OSE Immunotherapeutics SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 37 in the last 12 months · 65 in all · newest Oct 29, 2026 · oldest 2025
- Decks
- 22 decks · latest Sep 30, 2026
Where OSE Immunotherapeutics SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:OSE · Home listing · This page | Euronext | France | EUR |
| LSE:0RAD | LSE | United Kingdom | EUR |
| gettex:6OP | gettex | Germany | EUR |
| LS Exchange:A14QXP | LS Exchange | Germany | EUR |
| Lang & Schwarz:A14QXP | Lang & Schwarz | Germany | EUR |
| Tradegate:6OP | Tradegate | Germany | EUR |
| Aquis:OSEP | Aquis | United Kingdom | EUR |
| Munich:6OP | Munich | Germany | EUR |
| OTC:ORPOF | OTC | United States | USD |
| Aquis:OSEP | Aquis | United Kingdom | EUR |
| Dusseldorf:6OP | Dusseldorf | Germany | EUR |
| Frankfurt:6OP | Frankfurt | Germany | EUR |
| Hamburg:6OP | Hamburg | Germany | EUR |
| Stuttgart:6OP | Stuttgart | Germany | EUR |
Log in to ask 6ix AI your own questions about OSE Immunotherapeutics SA.